tci Medicare Compliance & Reimbursement - 2005 Issue 41
PHARMACEUTICALS: HHS Reports Drug Payouts Are More Than Adequate
Subscribe or sign in to view the full article.
Article Overview
This article reviews an HHS Office of Inspector General report on Medicare drug payment levels under the average sales price system. It explains, at a high level, why the findings matter to oncology and hematology practices, CMS, and providers concerned about drug reimbursement policy. The piece is relevant to readers tracking Medicare payment methodology, oncology drug pricing, and federal audit findings.
Why This Topic Matters
The article addresses whether Medicare payments for physician-administered drugs are aligned with provider costs, a question that affects oncology and hematology practices, CMS policy, and future reimbursement discussions.
What You Will Learn
- What the HHS OIG reviewed in relation to Medicare drug reimbursement
- How the article frames the impact of the average sales price system on oncology-related payments
- Why the report is relevant to physician practices and federal payment policy
- Which provider specialties were included in the payment analysis
- How audit findings can influence Medicare reimbursement discussions
Who Should Read This
- Medical coders
- Billing staff
- Compliance professionals
- Oncology practice managers
- Hematology/oncology administrators
- Healthcare reimbursement analysts
Subscribe or sign in to view the full article.
Thank you for choosing Find-A-Code, please Sign In to remove ads.
Quick, Current, Complete - www.findacode.com